AKT1 and breast carcinoma: Rosiglitazone induces a dose-dependent negative interference with the PI3K/AKT cascade through the upregulation of tumor suppressor gene phosphatase and tensin homolog on chromosome ten (PTEN), thus determining breast cancer cell growth inhibition in MCF-7 cells [18].